In 2022, nivolumab was granted marketing authorization for adjuvant treatment in patients at high risk of recurrence following surgery for localized invasive muscle urothelial carcinoma, who express PD-L1 on the operative specimen. We aimed to investigate its real-world utilization.
No takes yet. Share an insight, caveat, or question.
Guilbert et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: